[1]汪 磊,陈 佳,李志虎,等.髂内动脉化疗栓塞在极高危非肌层浸润性膀胱癌经尿道电切术后的应用及价值[J].介入放射学杂志,2020,29(10):988-992.
 WANG Lei,CHEN Jia,LI Zhihu,et al.Application and clinical value of intra-arterial chemoembolization via internal iliac artery in treating extremely high-risk non-muscle invasive bladder cancer after trans-urethral resection[J].journal interventional radiology,2020,29(10):988-992.
点击复制

髂内动脉化疗栓塞在极高危非肌层浸润性膀胱癌经尿道电切术后的应用及价值()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年10
页码:
988-992
栏目:
肿瘤介入
出版日期:
2020-10-25

文章信息/Info

Title:
Application and clinical value of intra-arterial chemoembolization via internal iliac artery in treating extremely high-risk non-muscle invasive bladder cancer after trans-urethral resection
作者:
汪 磊 陈 佳 李志虎 王 刚 果宏峰 张侃玺 何 山 李宁忱
Author(s):
WANG Lei CHEN Jia LI Zhihu WANG Gang GUO Hongfeng ZHANG Kanxi HE Shan LI Ningchen.
Department of Urology, Shougang Hospital of Peking University, Wujieping Urology Center of Peking University, Beijing 100144, China
关键词:
【关键词】 极高危 非肌层浸润性膀胱癌 髂内动脉化疗栓塞术 复发 根治性膀胱切除
文献标志码:
A
摘要:
【摘要】 目的 极高危非肌层浸润性膀胱癌具有很高的复发和进展风险。明确双侧髂内动脉化疗栓塞术(IAC)经尿道电切术后辅助措施的价值。方法 回顾性分析2015年1月至2017年12月收治的该类患者38例,均接受经尿道膀胱肿瘤电切术及术后规律膀胱灌注治疗(卡介苗或表柔吡星/吡柔吡星),根据是否接受IAC分为IAC组及对照组。IAC组在电切术后2周内接受第1疗程IAC,再间隔3~4周行第2疗程IAC,化疗方案:顺铂60 mg/m2,吡柔比星25 mg/m2。术后随访指标包括无复发生存时间、随访期间进展率及切除膀胱率等。 结果 IAC组12例,对照组26例,平均随访时间 (30.1±12.4)个月。IAC组与对照组在主要观察指标上的比较如下:无复发生存时间 (20.3±14.1)个月比 (8.9±7.2)个月,(P=0.002),1年无复发生存率66.7%比26.9%,(P=0.02),2年无复发生存率33.3%比7.7%,(P=0.07),随访期间进展率33.3%比46.2%,(P=0.46),切除膀胱率25.0%比46.2%,(P=0.21)。结论 对于极高危非肌层浸润性膀胱癌患者,在经尿道电切术后辅助双侧髂内动脉化疗栓塞有助于延缓疾病的复发。

参考文献/References:

[1] Martin- Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high- grade T1 bladder cancer: a meta- analysis of 15,215 patients[J]. J Clin Oncol, 2015, 33: 643- 650.
[2] Mannas MP, Lee T, Nykopp TK, et al. A risk- stratified approach to the management of high- grade T1 bladder cancer[J]. Curr Opin Urol, 2018, 28: 563-569.
[3] 中国研究型医院学会泌尿外科学专业委员会,中国医疗保健国际交流促进会泌尿健康促进分会,中国医疗保健国际交流促进会循证医学分会,等. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018年标准版)[J]. 现代泌尿外科杂志, 2019, 24:516-542.
[4] Babjuk M, Burger M, Comperat EM, et al. European Association of Urology guidelines on non- muscle- invasive bladder cancer (TaT1 and carcinoma in situ): 2019 update[J]. Eur Urol, 2019, 76: 639- 657.
[5] Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2016[J]. Eur Urol, 2017, 71: 447-461.
[6] 邓康俐,崔殿生,贾全安,等. 新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较[J]. 肿瘤防治研究, 2019, 46:363-366.
[7] 王 琦,徐佳伟,欧彤文,等. 经尿道膀胱肿瘤切除术后联合髂内动脉化疗治疗肌层浸润性膀胱癌疗效分析[J]. 微创泌尿外科杂志, 2016, 5:229-232.
[8] Umeyama T, Mashimo T, Nakazato H, et al. Intra- arterial infusion therapy following alteration of pelvic blood flow and concurrent radiation therapy for invasive bladder cancer[J]. Int J Urol, 1996, 3: S44-S45.
[9] Azuma H, Inamoto T, Takahara K, et al. The novel bladder preservation therapy BOAI- CDDP- radiation(OMC- regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis[J]. Int J Oncol, 2014, 44: 1895-1903.
[10] Azuma H, Inamoto T, Takahara K, et al. Tetramodal therapy using balloon- occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer[J]. Int J Oncol, 2019, 54: 167-176.
[11] Yamamoto K, Yamamoto K, Nakai G, et al. Novel software-assisted hemodynamic evaluation of pelvic flow during chemo-perfusion of pelvic arteries for bladder cancer: double- versus single-balloon technique[J]. Cardiovasc Intervent Radiol, 2016, 39: 824- 830.
[12] Kakizaki H, Suzuki H, Kubota Y, et al. Preoperative one- shot intra- arterial infusion chemotherapy for bladder cancer[J]. Cancer Chemother Pharmacol, 1987, 20: S15-S19.
[13] Kobayashi M, Sugaya Y, Yuzawa M, et al. Intra- arterial infusion chemotherapy for superficial bladder cancer[J]. Hinyokika Kiyo, 1999, 45: 605- 607.
[14] Kano H, Miwa S, Koshida K, et al. Successful treatment of a large superficial bladder cancer with neoadjuvant arterial infusion chemotherapy: a case report[J]. Case Rep Oncol, 2018, 11: 383-387.
[15] 王玉林,胡荣奎,贾中芝,等. 动脉内栓塞治疗晚期膀胱癌22例临床总结[J]. 介入放射学杂志, 2015, 24:311-313.
[16] 游建雄,王精兵,赵 庆,等. 超选择膀胱动脉化疗栓塞治疗晚期膀胱癌伴出血的疗效分析[J]. 介入放射学杂志, 2019, 28:647-651.
[17] 童 强,姚立欣,黄金明,等. 髂内动脉化疗栓塞联合经尿道膀胱肿瘤电切术治疗晚期膀胱癌17例[J]. 介入放射学杂志, 2013, 22:148-151.
[18] Liu Z, Ye Y, Li X, et al. The effects of intra- arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer[J]. World J Urol, 2018, 36: 1191-1200.
[19] Sun F, Zhao R, Zhu Y, et al. A prospective comparison of intra- arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high- risk non-muscle invasive bladder cancer[J]. Cancer Chemother Pharmacol, 2017, 79: 1099-1107.
[20] Huang B, Zheng J, Yao Z, et al. Efficacy of intra- arterial chemo- therapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder- sparing surgery: a retrospective study[J]. World J Urol, 2019, 37: 823-829.

备注/Memo

备注/Memo:
(收稿日期:2019-12-22)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2020-10-19